CRISPR Therapeutics AG [CRSP] stock is trading at $86.06, up 2.46%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CRSP shares have gain 4.67% over the last week, with a monthly amount glided 36.89%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, February 2024, CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results. In a post published today on Yahoo Finance, — CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain —.
From an analyst’s perspective:
Previously, TD Cowen downgraded its rating to Underperform on December 11, 2023, and kept the price target unchanged to $30. On October 17, 2023, downgrade downgraded it’s rating to Neutral. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $82 on September 27, 2023. Citigroup upgraded its rating to a Buy. William Blair started tracking with a Outperform rating for this stock on May 30, 2023, and assigned it a price target of $75. In a note dated April 13, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $72 on this stock.
CRISPR Therapeutics AG [CRSP] stock has fluctuated between $37.55 and $91.10 over the past year. Currently, Wall Street analysts expect the stock to reach $130.69 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $86.06 at the most recent close of the market. An investor can expect a potential return of 51.86% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
CRISPR Therapeutics AG [NASDAQ:CRSP] reported sales of 371.21M for the trailing twelve months, which represents a growth of 3353333.33%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 83.92 points at the first support level, and at 81.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 87.52, and for the 2nd resistance point, it is at 88.99.
CRISPR Therapeutics AG [CRSP] reported earnings per share of $1.1 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.07/share, meaning a difference of $1.17 and a surprise factor of 1,671.40%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.41 per share as compared to estimates of -$1.95 per share, a difference of $0.54 representing a surprise of 27.70%.
Ratios To Look Out For
For context, CRISPR Therapeutics AG’s Current Ratio is 17.54. In addition, the Quick Ratio stands at 17.54 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 19.52, the price to book ratio is 3.66.
Transactions by insiders
Recent insider trading involved Kulkarni Samarth, Chief Executive Officer, that happened on Feb 20 when 6370.0 shares were sold. General Counsel and Secretary, KASINGER JAMES R. completed a deal on Feb 20 to sell 1913.0 shares. Meanwhile, Chief Executive Officer Kulkarni Samarth sold 20000.0 shares on Feb 15.
